
ImmunityBio (IBRX) Stock Forecast & Price Target
ImmunityBio (IBRX) Analyst Ratings
Bulls say
ImmunityBio has demonstrated strong financial growth, with Q4 2024 net product revenue increasing by 21% to $7.2 million, driven by robust sales of ANKTIVA following its FDA approval. The product candidate has shown promising long-term durability and efficacy, as reflected in previously reported disease-free survival rates and improved complete response rates in recent trials. Additionally, the company's strategic collaborations, regulatory progress in Europe, and projected revenue growth from ANKTIVA, anticipated to reach $137.4 million by 2025 and $4.3 billion by 2034, further enhance the positive outlook for ImmunityBio’s stock.
Bears say
ImmunityBio has experienced ongoing operating losses since its inception, with an outlook suggesting that profitability may remain unattainable for several more years, which raises concerns about the sustainability of its financial model. Additionally, the company's debt and revenue interest liability are likely to strain cash flows and hinder its ability to secure further capital, potentially limiting growth opportunities. Further complicating its prospects, the company faces skepticism regarding the regulatory approval process and manufacturing capabilities, along with a declining complete response rate for its therapies, which collectively contribute to a negative sentiment around its stock.
This aggregate rating is based on analysts' research of ImmunityBio and is not a guaranteed prediction by Public.com or investment advice.
ImmunityBio (IBRX) Analyst Forecast & Price Prediction
Start investing in ImmunityBio (IBRX)
Order type
Buy in
Order amount
Est. shares
0 shares